CA2765899A1 - Drive mechanism for an injection device and an injection device with such a drive mechanism - Google Patents
Drive mechanism for an injection device and an injection device with such a drive mechanism Download PDFInfo
- Publication number
- CA2765899A1 CA2765899A1 CA2765899A CA2765899A CA2765899A1 CA 2765899 A1 CA2765899 A1 CA 2765899A1 CA 2765899 A CA2765899 A CA 2765899A CA 2765899 A CA2765899 A CA 2765899A CA 2765899 A1 CA2765899 A1 CA 2765899A1
- Authority
- CA
- Canada
- Prior art keywords
- drive
- drive member
- piston
- drive mechanism
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000007246 mechanism Effects 0.000 title claims abstract description 58
- 238000002347 injection Methods 0.000 title claims abstract description 37
- 239000007924 injection Substances 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 63
- 230000001419 dependent effect Effects 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 50
- 108010011459 Exenatide Proteins 0.000 description 47
- 229960001519 exenatide Drugs 0.000 description 47
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 239000002585 base Substances 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- HTQBXNHDCUEHJF-URRANESESA-N exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)C(C)O)C(C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-URRANESESA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09009214 | 2009-07-15 | ||
| EP09009214.9 | 2009-07-15 | ||
| PCT/EP2010/060127 WO2011006925A1 (en) | 2009-07-15 | 2010-07-14 | Drive mechanism for an injection device and an injection device with such a drive mechanism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2765899A1 true CA2765899A1 (en) | 2011-01-20 |
Family
ID=41480147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2765899A Abandoned CA2765899A1 (en) | 2009-07-15 | 2010-07-14 | Drive mechanism for an injection device and an injection device with such a drive mechanism |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8517992B2 (enExample) |
| EP (1) | EP2453955B1 (enExample) |
| JP (1) | JP5701871B2 (enExample) |
| CN (1) | CN102470213A (enExample) |
| AU (1) | AU2010272600A1 (enExample) |
| BR (1) | BR112012000795A2 (enExample) |
| CA (1) | CA2765899A1 (enExample) |
| DK (1) | DK2453955T3 (enExample) |
| IL (1) | IL217420A0 (enExample) |
| WO (1) | WO2011006925A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2475573C (en) | 2002-02-11 | 2013-03-26 | Antares Pharma, Inc. | Intradermal injector |
| EP1850892B2 (en) | 2005-01-24 | 2023-04-19 | Antares Pharma, Inc. | Prefilled needle assisted syringe jet injector |
| WO2007131025A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Injector with adjustable dosing |
| US8251947B2 (en) | 2006-05-03 | 2012-08-28 | Antares Pharma, Inc. | Two-stage reconstituting injector |
| CN101868273B (zh) | 2007-10-02 | 2014-10-15 | 莱蒙德尔有限公司 | 外部药泵 |
| EP2990067B1 (en) | 2008-03-10 | 2019-09-04 | Antares Pharma, Inc. | Injector safety device |
| ES2738539T3 (es) | 2008-08-05 | 2020-01-23 | Antares Pharma Inc | Inyector de dosis múltiples |
| ES2988196T3 (es) | 2009-03-20 | 2024-11-19 | Antares Pharma Inc | Sistema de inyección de agentes peligrosos |
| CN103442748B (zh) * | 2011-02-19 | 2016-08-10 | 图什医疗有限公司 | 紧凑型医用泵装置 |
| US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
| US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
| DK2822618T3 (da) | 2012-03-06 | 2024-01-22 | Antares Pharma Inc | Forfyldt nål med brudkraftfunktion |
| EP4186545A1 (en) | 2012-04-06 | 2023-05-31 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
| US9364611B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
| CN102793966B (zh) * | 2012-08-02 | 2014-04-16 | 联合质量实业有限公司 | 便携可编程自动给药装置 |
| FI3659647T3 (fi) | 2013-02-11 | 2024-03-28 | Antares Pharma Inc | Neula-avusteinen suihkuinjektiolaite, jolla on pienennetty liipaisinvoima |
| EP3572108A1 (en) | 2013-03-11 | 2019-11-27 | Antares Pharma, Inc. | Dosage injector with pinion system |
| WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
| TWI689326B (zh) * | 2014-08-06 | 2020-04-01 | 加拿大商複製細胞生命科學公司 | 注射裝置 |
| US10765811B2 (en) | 2014-12-08 | 2020-09-08 | Genentech, Inc. | Versatile syringe platform |
| DE102015214091A1 (de) * | 2015-07-24 | 2017-01-26 | Vetter Pharma-Fertigung GmbH & Co. KG | Injektionseinrichtung und Verfahren zum Betreiben einer Injektionseinrichtung |
| DE102015214088A1 (de) * | 2015-07-24 | 2017-01-26 | Vetter Pharma-Fertigung GmbH & Co. KG | Injektionseinrichtung und Verfahren zum Betreiben einer Injektionseinrichtung |
| US10576207B2 (en) | 2015-10-09 | 2020-03-03 | West Pharma. Services IL, Ltd. | Angled syringe patch injector |
| JP7044708B2 (ja) | 2015-10-09 | 2022-03-30 | ウェスト ファーマ サービシーズ イスラエル リミテッド | カスタマイズシリンジの充填方法 |
| JP6513297B2 (ja) | 2016-01-21 | 2019-05-22 | ウェスト ファーマ サービシーズ イスラエル リミテッド | 自動注射器、受け入れフレーム及び自動注射器におけるカートリッジの接続方法 |
| EP3405229A1 (en) | 2016-01-21 | 2018-11-28 | West Pharma. Services Il, Ltd. | Needle insertion and retraction mechanism |
| JP6885960B2 (ja) | 2016-01-21 | 2021-06-16 | ウェスト ファーマ サービシーズ イスラエル リミテッド | 視覚的インジケータを有する薬剤デリバリデバイス |
| WO2017161076A1 (en) | 2016-03-16 | 2017-09-21 | Medimop Medical Projects Ltd. | Staged telescopic screw assembly having different visual indicators |
| US11730892B2 (en) | 2016-08-01 | 2023-08-22 | West Pharma. Services IL, Ltd. | Partial door closure prevention spring |
| JP6869327B2 (ja) | 2016-08-01 | 2021-05-12 | ウェスト ファーマ サービシーズ イスラエル リミテッド | 回転防止カートリッジ |
| EP3315154B1 (de) | 2016-10-28 | 2021-07-07 | maxon international ag | Zweistufiger teleskopspindelantrieb |
| CN110869072B (zh) | 2017-05-30 | 2021-12-10 | 西部制药服务有限公司(以色列) | 用于穿戴式注射器的模块化驱动机构 |
| CN111973841A (zh) * | 2019-05-22 | 2020-11-24 | 上海微创生命科技有限公司 | 输注设备 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52621B1 (en) * | 1981-02-12 | 1988-01-06 | Turner Robert Charles | Dose metering plunger devices for use with syringes |
| US5269762A (en) | 1992-04-21 | 1993-12-14 | Sterling Winthrop, Inc. | Portable hand-held power assister device |
| DE19717107B4 (de) * | 1997-04-23 | 2005-06-23 | Disetronic Licensing Ag | System aus Behältnis und Antriebsvorrichtung für einen Kolben, der in dem ein Medikamentfluid enthaltenden Behältnis gehalten ist |
| US5893838A (en) * | 1997-08-15 | 1999-04-13 | Therox, Inc. | System and method for high pressure delivery of gas-supersaturated fluids |
| PL191327B1 (pl) * | 1998-01-30 | 2006-04-28 | Novo Nordisk As | Strzykawka do podawania ustalonych dawek lekarstwa z naboju |
| US6248093B1 (en) * | 1998-10-29 | 2001-06-19 | Minimed Inc. | Compact pump drive system |
| ATE318157T1 (de) * | 1999-08-05 | 2006-03-15 | Becton Dickinson Co | Stiftförmige medikamentenabgabevorrichtung |
| US6716198B2 (en) | 2000-05-18 | 2004-04-06 | Novo Nordisk A/S | Injection device |
| EP1641516A4 (en) * | 2003-06-09 | 2010-03-03 | Nipro Diabetes Systems Inc | COUPLING SYSTEM FOR INFUSION PUMP |
| JP4549079B2 (ja) * | 2004-03-05 | 2010-09-22 | パナソニック株式会社 | 医療用投与器具 |
| WO2006078817A2 (en) * | 2005-01-21 | 2006-07-27 | Medrad, Inc. | Injectors, injector systems and methods for injecting fluids |
| EP1904126B1 (en) * | 2005-07-08 | 2011-08-10 | Novo Nordisk A/S | Injection device |
| DE102006004563A1 (de) * | 2006-01-17 | 2007-07-19 | Tecpharma Licensing Ag | Ausfahrbarer Dosierknopf |
| DE102006038103B4 (de) * | 2006-08-14 | 2017-02-23 | Tecpharma Licensing Ag | Injektionsvorrichtung mit variabler Gewindeführung |
-
2010
- 2010-07-14 AU AU2010272600A patent/AU2010272600A1/en not_active Abandoned
- 2010-07-14 CN CN201080030691XA patent/CN102470213A/zh active Pending
- 2010-07-14 EP EP10732713.2A patent/EP2453955B1/en active Active
- 2010-07-14 DK DK10732713.2T patent/DK2453955T3/en active
- 2010-07-14 US US13/384,049 patent/US8517992B2/en active Active
- 2010-07-14 WO PCT/EP2010/060127 patent/WO2011006925A1/en not_active Ceased
- 2010-07-14 JP JP2012520023A patent/JP5701871B2/ja active Active
- 2010-07-14 CA CA2765899A patent/CA2765899A1/en not_active Abandoned
- 2010-07-14 BR BR112012000795A patent/BR112012000795A2/pt not_active IP Right Cessation
-
2012
- 2012-01-08 IL IL217420A patent/IL217420A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120220941A1 (en) | 2012-08-30 |
| US8517992B2 (en) | 2013-08-27 |
| CN102470213A (zh) | 2012-05-23 |
| WO2011006925A1 (en) | 2011-01-20 |
| JP5701871B2 (ja) | 2015-04-15 |
| BR112012000795A2 (pt) | 2016-02-23 |
| IL217420A0 (en) | 2012-02-29 |
| EP2453955B1 (en) | 2015-08-19 |
| EP2453955A1 (en) | 2012-05-23 |
| AU2010272600A1 (en) | 2012-02-02 |
| JP2012532721A (ja) | 2012-12-20 |
| DK2453955T3 (en) | 2015-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2453955B1 (en) | Drive mechanism for an injection device and an injection device with such a drive mechanism | |
| CA2762043C (en) | Dose setting mechanism for a drug delivery device | |
| US8961020B2 (en) | Thrust bearing assembly, drive train, and medicament delivery device | |
| EP2475410B1 (en) | Drive mechanism for a medication delivery device and medication delivery device | |
| EP2512563B1 (en) | Dose setting mechanism with maximum dose limiting element | |
| US9089656B2 (en) | Spindle and bearing combination and drug delivery device | |
| US20120209200A1 (en) | Drive Assembly for a Pen-Type Injector and Pen-Type Injector with a Drive Assembly | |
| US20120253288A1 (en) | Reminder device for drug delivery devices | |
| EP2488234A1 (en) | Drug delivery device | |
| WO2010112563A1 (en) | Medical device having a mechanism and use of a low-friction synthetic material within a medical device | |
| HK1177704A (en) | Dose setting mechanism with maximum dose limiting element | |
| HK1177704B (en) | Dose setting mechanism with maximum dose limiting element | |
| HK1168810A (en) | Dose setting mechanism for a drug delivery device for limiting dose setting corresponding to amount of medicament left | |
| HK1168810B (en) | Dose setting mechanism for a drug delivery device for limiting dose setting corresponding to amount of medicament left | |
| HK1168056A (en) | Spindle and bearing combination and drug delivery device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20150714 |